United Kingdom

People: Allergan plc (AGN.N)

AGN.N on New York Stock Exchange

9:10pm BST
Change (% chg)

$0.54 (+0.33%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Saunders, Brenton 

Mr. Brenton L. Saunders is Chairman of the Board, President, Chief Executive Officer of the Company. Mr. Saunders is Chairman, President and Chief Executive Officer of Allergan and has served in the role of President and Chief Executive Officer since July 2014 and of Chairman since October 2016, having previously served as Chief Executive Officer and President of Forest Laboratories, Inc. (“Forest”), and as a director of Forest, prior to its acquisition by Allergan (then known as Actavis plc (“Actavis”). Prior to that, he served as Chief Executive Officer of Bausch + Lomb Incorporated, a leading global eye health company, serving in this capacity from March 2010 until August 2013. Mr. Saunders also held a number of leadership positions at Schering-Plough, including the position of President of Global Consumer Health Care and was named head of integration for the company’s merger with Merck & Co. and for Schering-Plough’s acquisition of Organon BioSciences. Before joining Schering-Plough, Mr. Saunders was a Partner and Head of Compliance Business Advisory at PricewaterhouseCoopers LLP. Prior to that, he was Chief Risk Officer at Coventry Health Care and Senior Vice President, Compliance, Legal and Regulatory at Home Care Corporation of America. Mr. Saunders began his career as Chief Compliance Officer for the Thomas Jefferson University Health System. Mr. Saunders serves on the Board of Directors of Cisco Systems, Inc. and RWJBarnabas Health, and is a member of the Business Council and PhRMA.

Basic Compensation

Total Annual Compensation, USD 9,985,320
Restricted Stock Award, USD 22,682,000
Long-Term Incentive Plans, USD --
All Other, USD 160,279
Fiscal Year Total, USD 32,827,600

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --